CareDx, Inc. (NASDAQ:CDNA) Stock Has Consensus Price Target of $70.33 According to Brokerages

CareDx, Inc. (NASDAQ:CDNA – Get Free Report) has received a consensus rating of “Moderate Buy” from the nine brokerages that are covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a hold recommendation, four have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $70.33.

CDNA has been the subject of several research reports. HC Wainwright reissued a “neutral” rating and set a $46.00 price objective on shares of CareDx in a research note on Friday, July 31st. BTIG Research boosted their target price on CareDx from $81.00 to $92.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Craig Hallum raised CareDx from a “hold” rating to a “buy” rating and set a $64.00 target price on the stock in a research report on Monday, August 3rd. Piper Sandler started coverage on CareDx in a report on Wednesday, November 11th. They set an “overweight” rating and a $100.00 target price for the company. Finally, Weiss Ratings upgraded CareDx from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, October 8th.

Check Out Our Latest Stock Report on CareDx

CareDx Price Performance

NASDAQ CDNA opened at $73.72 on Thursday. CareDx has a 12 month low of $15.15 and a 12 month high of $90.87. The company has a market capitalization of $3.87 billion, a P/E ratio of 120.92 and a beta of 2.51. The company’s 50 day simple moving average is $66.80 and its 200 day simple moving average is $36.97.

CareDx (NASDAQ:CDNA – Get Free Report) last issued its earnings results on Thursday, October 29th. The company reported $0.70 earnings per share for the quarter, topping analysts’ consensus estimates of $0.25 by $0.45. The firm had revenue of $139.36 million during the quarter, compared to analysts’ expectations of $121.96 million. CareDx had a net margin of 25.86% and a return on equity of 9.74%. The firm’s revenue for the quarter was up 39.3% compared to the same quarter last year. During the same period last year, the firm posted $0.03 earnings per share. On average, analysts anticipate that CareDx will post 1.00 earnings per share for the current year.

Insider Transactions at CareDx

In other CareDx news, Director Michael Goldberg sold 13,800 shares of the company’s stock in a transaction dated Thursday, November 12th. The shares were sold at an average price of $79.15, for a total transaction of $1,092,270.00. Following the completion of the sale, the director directly owned 48,526 shares of the company’s stock, valued at approximately $3,840,832.90. This represents a 22.14% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Keith Kennedy sold 61,961 shares of the firm’s stock in a transaction dated Thursday, November 5th. The stock was sold at an average price of $77.82, for a total transaction of $4,821,805.02. Following the completion of the transaction, the chief financial officer owned 199,147 shares of the company’s stock, valued at approximately $15,497,619.54. The trade was a 23.73% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 77,858 shares of company stock worth $6,080,346 in the last three months. 2.40% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On CareDx

A number of large investors have recently made changes to their positions in CDNA. BlackRock Inc. purchased a new position in CareDx during the 2nd quarter valued at about $137,219,000. Bamco Inc. NY acquired a new position in shares of CareDx in the 2nd quarter valued at about $55,214,000. Bank of America Corp DE purchased a new stake in shares of CareDx in the second quarter worth approximately $16,297,000. Palo Alto Investors LP purchased a new stake in shares of CareDx in the second quarter worth approximately $15,158,295. Finally, Jupiter Topco LLC purchased a new stake in shares of CareDx in the second quarter worth approximately $9,673,000.

CareDx Company Profile

(Get Free Report)

CareDx, Inc. is a precision medicine company focused on organ transplantation. It develops and provides diagnostic tests and related services to help clinicians assess transplant recipients and monitor their health over time. Its offerings include AlloSure, a donor-derived cell-free DNA test used to help monitor for organ rejection, and AlloMap, a gene-expression test used in heart transplant care. CareDx also provides histocompatibility testing, clinical tools, and services designed to support patients and transplant care teams.

Recommended Stories

Analyst Recommendations for CareDx (NASDAQ:CDNA)

Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter.